Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey
- PMID: 17394656
- PMCID: PMC1851704
- DOI: 10.1186/1472-6947-7-8
Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey
Abstract
Background: For shared decision making doctors need to communicate the effectiveness of therapies such that patients can understand it and discriminate between small and large effects. Previous research indicates that patients have difficulties in understanding risk measures. This study aimed to test the hypothesis that lay people may be able to discriminate between therapies when their effectiveness is expressed in terms of postponement of an adverse disease event.
Methods: In 2004 a random sample of 1,367 non-institutionalized Danes aged 40+ was interviewed in person. The participants were asked for demographic information and asked to consider a hypothetical preventive drug treatment. The respondents were randomized to the magnitude of treatment effectiveness (heart attack postponement of 1 month, 6 months, 12 months, 2 years, 4 years and 8 years) and subsequently asked whether they would take such a therapy. They were also asked whether they had hypercholesterolemia or had experienced a heart attack.
Results: In total 58% of the respondents consented to the hypothetical treatment. The proportions accepting treatment were 39%, 52%, 56%, 64%, 67% and 73% when postponement was 1 month, 6 months, 12 months, 2 years, 4 years and 8 years respectively. Participants who thought that the effectiveness information was difficult to understand, were less likely to consent to therapy (p = 0.004).
Conclusion: Lay people can discriminate between levels of treatment effectiveness when they are presented in terms of postponement of an adverse event. The results indicate that such postponement is a comprehensible measure of effectiveness.
References
-
- Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 164:208–11. 1996 Feb 19. - PubMed
-
- Perrault S, Blais L, Lamarre D, Dragomir A, Berbiche D, lalonde L, laurier C, St-Maurice F, Collin J. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667–74. doi: 10.1007/s00228-005-0980-z. Epub 2005 Oct 19. - DOI - PubMed
-
- Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P, Russell I, Study Steering Group Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004;21:347–354. doi: 10.1093/fampra/cmh402. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical